VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
VAXCYTE, INC. (PCVX) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of 1.15 million shares as of 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber · last filed 2024-11-05
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1.15M shares.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1.27M shares.
- 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1.20M shares.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 753.46K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number |
|---|---|
| 2024-09-30 | 1.15M shares 10-Q · filed 2024-11-05 |
| 2024-06-30 | 1.27M shares 10-Q · filed 2024-08-06 |
| 2024-03-31 | 1.20M shares 10-Q · filed 2024-05-08 |
| 2023-12-31 | 753.46K shares 10-Q · filed 2024-11-05 |
| 2023-09-30 | 700.42K shares 10-Q · filed 2023-11-06 |
| 2023-06-30 | 797.26K shares 10-Q · filed 2023-08-08 |
| 2023-03-31 | 773.66K shares 10-Q · filed 2023-05-08 |
| 2022-12-31 | 456.77K shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 420.17K shares 10-Q · filed 2022-11-07 |
| 2022-06-30 | 429.02K shares 10-Q · filed 2022-08-08 |
| 2022-03-31 | 373.44K shares 10-Q · filed 2022-05-09 |
| 2021-12-31 | 0.00 shares 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |